Orca Bio's strategy is not to sell a standalone product, but to replace the entire conventional stem cell transplant procedure. They integrate their manufacturing process directly into the existing patient and donor workflow, leveraging established infrastructure like the National Marrow Donor Program to deliver a superior alternative.

Eupraxia's strategy for its Eosinophilic Esophagitis (EOE) drug piggybacks on existing procedures. Since EOE patients already undergo endoscopies, the local injection is administered during the same visit. This minimizes the procedural burden on patients and doctors, streamlining adoption and making the hyper-local delivery model feasible and efficient.

The backend infrastructure built by compound pharmacies to serve telehealth giants like Hims and Ro is now mature. This creates an opportunity for new brands to quickly launch and ship prescription products, effectively using these pharmacies as a platform for regulated health and wellness DTC.

TrueMed's model allows consumers to use tax-free HSA/FSA funds for preventative health measures like gym memberships and healthy food. By facilitating a "letter of medical necessity," it effectively reclassifies these lifestyle interventions as legitimate medical expenses, creating a financial incentive for prevention.

Unlike competitors, Calm intentionally integrates with existing healthcare payers and providers rather than building its own therapist network. This is a deliberate strategic choice to reduce complexity for users navigating an already overwhelming healthcare system.

AdaptDx plans to first target specific, high-need clinical conditions like heart failure to secure FDA approval and reimbursement. This clinical validation and revenue stream will then fund the miniaturization and expansion into the broader consumer health and wellness market, bridging the gap between medical care and daily life.

Gaining FDA approval is not the finish line. Many innovative devices fail because they lack a clear reimbursement strategy. Founders must build the economic case for payers and providers in concert with their clinical and regulatory strategy from day one.

Pharma companies now partner with telehealth providers to offer coupons that reduce the cost of the physician consultation itself. This marketing tactic incentivizes patients to seek a prescription for a specific drug, raising questions about overprescribing and conflicts of interest.

Direct-to-consumer telehealth companies like Hims achieve rapid growth via a vertically integrated model of marketing, medical groups, and pharmacies. This structure allows them to generate revenue from selling medicines, a more scalable business than relying on fees from the practice of medicine alone.